BACKGROUND/AIMS: Chemokines are small peptides which are potent activators and chemoattractants for leucocyte subpopulations. Their action is mediated by a family of seven transmembrane spanning G-protein coupled receptors. The aims of this study were to examine the expression of the chemokine receptors CCR1, CCR3, CCR5, CXCR3, and CXCR4 in the conjunctiva of patients with vernal keratoconjunctivitis (VKC) and to investigate the phenotype of inflammatory cells expressing these chemokine receptors. METHODS: Conjunctival biopsy specimens from 16 patients with active VKC, and eight control subjects were studied by immunohistochemical techniques using a panel of monoclonal antibodies directed against human CCR1, CCR3, CCR5, CXCR3, and CXCR4. The phenotype of inflammatory cells expressing chemokine receptors was examined by double immunohistochemistry. RESULTS: In the normal conjunctiva, few inflammatory cells expressed CXCR3 in five of eight specimens. There was no immunoreactivity for CCR1, CCR3, CCR5, and CXCR4. In VKC specimens, membranous immunoreactivity for CXCR3 was noted on inflammatory cells in all specimens. Compared with control specimens, VKC specimens showed significantly more inflammatory cells expressing CXCR3 (54.3 (SD 34.3) v 3.3 (5.0); p<0.001). Few CCR1+, CCR3+, CCR5+, and CXCR4+ inflammatory cells were observed in only three of 16 specimens. Double immunohistochemistry revealed that all CXCR3 positive inflammatory cells were CD3 positive T lymphocytes and that 61.7% (3.7%) of the infiltrating T lymphocytes were reactive for CXCR3. CONCLUSIONS: CXCR3 is the predominant chemokine receptor and is expressed abundantly on T lymphocytes in the conjunctiva of patients with active VKC. These data suggest a potential role for CXCR3 receptors in the regulation of lymphocyte recruitment within conjunctiva of VKC patients. New therapeutic strategies that block CXCR3 may inhibit T lymphocyte recruitment and suppress adverse inflammatory reactions.
BACKGROUND/AIMS: Chemokines are small peptides which are potent activators and chemoattractants for leucocyte subpopulations. Their action is mediated by a family of seven transmembrane spanning G-protein coupled receptors. The aims of this study were to examine the expression of the chemokine receptors CCR1, CCR3, CCR5, CXCR3, and CXCR4 in the conjunctiva of patients with vernal keratoconjunctivitis (VKC) and to investigate the phenotype of inflammatory cells expressing these chemokine receptors. METHODS: Conjunctival biopsy specimens from 16 patients with active VKC, and eight control subjects were studied by immunohistochemical techniques using a panel of monoclonal antibodies directed against humanCCR1, CCR3, CCR5, CXCR3, and CXCR4. The phenotype of inflammatory cells expressing chemokine receptors was examined by double immunohistochemistry. RESULTS: In the normal conjunctiva, few inflammatory cells expressed CXCR3 in five of eight specimens. There was no immunoreactivity for CCR1, CCR3, CCR5, and CXCR4. In VKC specimens, membranous immunoreactivity for CXCR3 was noted on inflammatory cells in all specimens. Compared with control specimens, VKC specimens showed significantly more inflammatory cells expressing CXCR3 (54.3 (SD 34.3) v 3.3 (5.0); p<0.001). Few CCR1+, CCR3+, CCR5+, and CXCR4+ inflammatory cells were observed in only three of 16 specimens. Double immunohistochemistry revealed that all CXCR3 positive inflammatory cells were CD3 positive T lymphocytes and that 61.7% (3.7%) of the infiltrating T lymphocytes were reactive for CXCR3. CONCLUSIONS:CXCR3 is the predominant chemokine receptor and is expressed abundantly on T lymphocytes in the conjunctiva of patients with active VKC. These data suggest a potential role for CXCR3 receptors in the regulation of lymphocyte recruitment within conjunctiva of VKC patients. New therapeutic strategies that block CXCR3 may inhibit T lymphocyte recruitment and suppress adverse inflammatory reactions.
Authors: M Uguccioni; C R Mackay; B Ochensberger; P Loetscher; S Rhis; G J LaRosa; P Rao; P D Ponath; M Baggiolini; C A Dahinden Journal: J Clin Invest Date: 1997-09-01 Impact factor: 14.808
Authors: H Soto; W Wang; R M Strieter; N G Copeland; D J Gilbert; N A Jenkins; J Hedrick; A Zlotnik Journal: Proc Natl Acad Sci U S A Date: 1998-07-07 Impact factor: 11.205
Authors: S Qin; J B Rottman; P Myers; N Kassam; M Weinblatt; M Loetscher; A E Koch; B Moser; C R Mackay Journal: J Clin Invest Date: 1998-02-15 Impact factor: 14.808
Authors: M Loetscher; B Gerber; P Loetscher; S A Jones; L Piali; I Clark-Lewis; M Baggiolini; B Moser Journal: J Exp Med Date: 1996-09-01 Impact factor: 14.307
Authors: T L Sørensen; M Tani; J Jensen; V Pierce; C Lucchinetti; V A Folcik; S Qin; J Rottman; F Sellebjerg; R M Strieter; J L Frederiksen; R M Ransohoff Journal: J Clin Invest Date: 1999-03 Impact factor: 14.808
Authors: R Bonecchi; G Bianchi; P P Bordignon; D D'Ambrosio; R Lang; A Borsatti; S Sozzani; P Allavena; P A Gray; A Mantovani; F Sinigaglia Journal: J Exp Med Date: 1998-01-05 Impact factor: 14.307
Authors: K E Cole; C A Strick; T J Paradis; K T Ogborne; M Loetscher; R P Gladue; W Lin; J G Boyd; B Moser; D E Wood; B G Sahagan; K Neote Journal: J Exp Med Date: 1998-06-15 Impact factor: 14.307
Authors: Daniel R Saban; Virginia Calder; Chuan-Hui Kuo; Nancy J Reyes; Darlene A Dartt; Santa J Ono; Jerry Y Niederkorn Journal: Curr Eye Res Date: 2013-01-02 Impact factor: 2.424
Authors: J Galicia-Carreón; C Santacruz; J Ayala-Balboa; A Robles-Contreras; S M Perez-Tapia; Y Garfias; E Hong; M C Jiménez-Martínez Journal: Clin Dev Immunol Date: 2013-12-04